Avecho Biotechnology’s Phase III clinical trial of cannabidiol as an insomnia treatment has received the go-ahead to finish. This could transform the fortunes and lives of insomniacs worldwide.
A Data Monitoring Board, independent of Avecho, (ASX : AVE), published an interim analysis on June 24, 2026. It recommended the study be continued to enroll its intended 519 participants.
A green light for a half-completed trial may not seem like an important development. Avecho’s CEO, Dr Paul Gavin says that this could not be farther from the truth.
Just two weeks earlier, Gavin was faced with the prospect of ‘winding the trial up after years of hard work and investment, making life difficult for the company moving forward ‘. He tells how lucky he is. MEDCAN24: “My life is very different now… Instead, it’s like now the world is my oyster.”
This all-or-nothing dynamic so common in the biotech sector, means Avecho is now in a ‘mad rush to finish the phase three trial and get it towards registration.’ Avecho would be the first CBD product to register with Australia’s Therapeutic Goods Administration as an over-the counter product if the trial results confirm the interim signals. This approval would close Australia’s prescription route for CBD insomnia treatment and give Avecho a monopoly.
Avecho’s CBD capsules TPM
A soft-gel cap containing synthetic CBD ultra-high purity combined with TPM proprietary technology is the product that’s at the heart of this trial.
CBD is a promising drug for a variety of ailments, but its poor absorption when consumed orally has frustrated many pharmaceutical developers. This makes it difficult to administer consistent doses that are up to pharmaceutical standards.
Avecho’s proprietary technology is Tocopheryl-Phosphate (TPM), which Gavin was credited to invent. The company claims that TPM increased CBD absorption by four times in canine tests compared to Epidiolex – the only CBD medication approved by the US Food and Drug Administration.
Avecho, Avecho investigators, and patients are all blinded as to the participants’ treatment. The study involves participants taking a daily dose of either 75mg or 150mg CBD over a period of eight weeks.
It is confirmed by the interim analysis that based upon the results of the 244 first participants the trial met the predefined criteria in order to proceed. That means it has detected an effect on at least 1 endpoint compared to placebo.
No serious adverse reactions were reported, which is crucial for CBD producers who are still fighting to have their products approved for safe consumption. The company believes that the product performs in a similar way to approved insomnia drugs.
Gavin said, “Although the results are not finalized and we’re still blinded in this study, it is more than likely that CBD works to treat insomnia.”
READ MORE…
Open door at a market
Low-dose CBD is only available to pharmacists in Australia since February 2021. No product has been clinically tested yet.
The Special Access Scheme in Australia, which is the route of prescription through which the medical cannabis industry has grown exponentially, only allows treatment when there are no approved medicines for an indication.
Gavin explained that as soon as Avecho’s CBD treatment is registered with the Therapeutic Goods Administration (TGA), this means ‘it becomes illegal for a similar CBD product to be prescribed for the same indication’ using the existing medicinal cannabis prescribing pathways available for unregistered medicines.
Registration would remove the need for a prescription or a GP visit, Gavin said, handing Avecho ‘direct access to the entire adult population whenever they walk into a pharmacy’. He called it a ‘huge commercial advantage over medicinal cannabis and prescription medicines’.
Sandoz, one of the largest generic drug companies in the world was attracted to Avecho by this opportunity. This pharma giant has licensed Australian rights by 2025, paying US$3m for the upfront payment and up to US$16m through milestones. It also pays a tiered rate of royalties between 14% and 19%.
Sandoz takes care of the TGA submission and will also handle supply and distribution. Gavin’s projects that, if successfully registered with the TGA, ‘I will get 20 to 50mUS every year, just for Australia… That’s before you factor in rest of world.’
Avecho values the Australian CBD over-the counter market at US$125m per year. This is compared to a global market for insomnia treatments that Avecho estimates will be worth US$9.5bn in 2033. An estimated 850m people worldwide suffer from insomnia. Gavin has now received the interim result and is in negotiations with several pharmaceutical companies in different international regions. Gavin hopes to secure licensing agreements for more territories by the second half 2026.
The US is experiencing a rescheduling under the Trump Administration that has changed the playing field in the US for drug companies developing cannabis-derived drugs. This follows deeper changes within the FDA which Gavin believes presents a ‘unique window of time under this presidency,’ and an opportunity Avecho is poised to take.
The regulator changed its stance in early 2026 and accepted a single, well-controlled, adequate trial with confirmatory evidence as the basis of approval. This was a departure from the longstanding requirement for two.
The US regulatory team that I sent to Australia visited Australia just a few months back and told us we had to get you before the FDA in Australia as quickly as humanly possible.
Most notably, he argues that with cannabis being in Schedule I for so long, ‘universities and pharma’ haven’t been actively conducting research and clinical trials.
“Australia and Europe got big head starts,” he said, claiming Avecho is on course to become only the second pharmaceutical CBD approved after Epidiolex, ‘for a much, much bigger indication’.gger indication’.